Physician profile
Gina R Singleton
NPI 1033104369
$1,152.05
in general payments reported to CMS, 2019-2025
11 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.80 · 2022: $161 · 2023: $228 · 2024: $508 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.67 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $250.23 | 2024 | Tolak |
| E.R. Squibb & Sons, L.L.C. | $175.13 | 2022-2025 | Sotyktu |
| Abbvie INC. | $158.26 | 2019-2025 | Skyrizi |
| Dermavant Sciences, INC. | $148.16 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $145.20 | 2022-2024 | |
| Janssen Biotech, INC. | $99.99 | 2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Sun Pharmaceutical Industries INC. | $30.16 | 2022 | |
| Pfizer INC. | $28.74 | 2022-2023 | |
| Genzyme Corporation | $23.15 | 2023 | |
| Leo Pharma INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.